- Home
- BCAN vs WINT Comparison
BCAN vs WINT Comparison
Compare BCAN & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAN
- WINT
- Stock Information
- Founded
- BCAN 2019
- WINT 1992
- Country
- BCAN Israel
- WINT United States
- Employees
- BCAN 7
- WINT N/A
- Industry
- BCAN Computer Software: Prepackaged Software
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAN Technology
- WINT Health Care
- Exchange
- BCAN Nasdaq
- WINT Nasdaq
- Market Cap
- BCAN 5.2M
- WINT 5.3M
- IPO Year
- BCAN N/A
- WINT 1995
- Fundamental
- Price
- BCAN $8.05
- WINT $0.48
- Analyst Decision
- BCAN
- WINT Hold
- Analyst Count
- BCAN 0
- WINT 1
- Target Price
- BCAN N/A
- WINT $18.00
- AVG Volume (30 Days)
- BCAN 11.1K
- WINT 1.9M
- Earning Date
- BCAN 01-01-0001
- WINT 11-26-2024
- Dividend Yield
- BCAN N/A
- WINT N/A
- EPS Growth
- BCAN N/A
- WINT N/A
- EPS
- BCAN N/A
- WINT N/A
- Revenue
- BCAN $754,768.00
- WINT N/A
- Revenue This Year
- BCAN N/A
- WINT N/A
- Revenue Next Year
- BCAN N/A
- WINT N/A
- P/E Ratio
- BCAN N/A
- WINT N/A
- Revenue Growth
- BCAN N/A
- WINT N/A
- 52 Week Low
- BCAN $7.80
- WINT $0.45
- 52 Week High
- BCAN $3,682.20
- WINT $22.32
- Technical
- Relative Strength Index (RSI)
- BCAN 48.51
- WINT 24.83
- Support Level
- BCAN $7.80
- WINT $0.53
- Resistance Level
- BCAN $8.30
- WINT $0.64
- Average True Range (ATR)
- BCAN 0.22
- WINT 0.07
- MACD
- BCAN 0.00
- WINT 0.08
- Stochastic Oscillator
- BCAN 36.76
- WINT 6.24
About BCAN BYND Cannasoft Enterprises Inc.
Femto Technologies Inc is an integrated software company. It owns and markets Benefit CRM, a proprietary customer relationship management CRM software product enabling small and medium sized businesses to optimize their day to day business activities such as sales management, personnel management, marketing, call center activities, and asset management.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.